Clinical trials: Pembrolizumab
Solid Tumor
HDCRT Plus Pembrolizumab in Advanced Malignancies
This study is a pilot study to evaluate high-dose conformal radiation therapy (HDCRT) administered in combination with pembrolizumab in patients with solid tumors.
- Trial name
- UVA-AM-001 (NCT02987166)
- Testing
- High-Dose Conformal Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- James Larner, MD
Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm
Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma
This phase 2 trial tests the safety and effectiveness of a cancer vaccine called LabVax 3(22)-23 and GM-CSF in combination with pembrolizumab in treating adenocarcinoma that has spread to other places in the body (advanced…
- Trial name
- NCT07859592
- Testing
- LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Adult Solid Neoplasm, Bladder Carcinoma
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
This phase I trial studies the side effects of vaccine therapy and pembrolizumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment, that…
- Conditions
- Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative
- Trial name
- NCT02432963
- Testing
- Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- City of Hope Medical Center
Cervical Cancer
Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer
This trial is a multicenter, single-arm, phase 2 study of pembrolizumab in combination with olaparib in recurrent or metastatic cervical cancer patients who had disease progression during or after platinum-based chemotherapy.
- Trial name
- NCT04641728
- Testing
- Pembrolizumab, Olaparib
- Where
- Japan
- Volunteers
- 28 people
- Sponsor
- Saitama Medical University International Medical Center
Carcinoma, Non-Small-Cell Lung
MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients
This is a phase II open-label randomized clinical trial of MK-3475 (Pembrolizumab) on previously treated non-small cell lung cancer (NSCLC) patients .
- Trial name
- NCT02574598
- Testing
- MK-3475, Docetaxel
- Where
- Mexico
- Volunteers
- 78 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03286114
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Breast Cancer, Metastatic Triple Negative
Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients
The purpose of this study is to find out what effects, good and/or bad, pembrolizumab has on the patient and areas of cancer in their body that did not receive radiation therapy.
- Trial name
- NCT02730130
- Testing
- Pembrolizumab, Radiotherapy
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
Head and neck squamous cell carcinoma (HNSCC) is one of the common malignant tumors in the world. More than 60% of HNSCC patients are locally advanced when first diagnosed.
- Trial name
- NCT06814067
- Testing
- Pembrolizumab, Ivonescimab, Surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Fudan University
Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma
Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
This phase II trial studies how well pembrolizumab works in treating patients with small bowel adenocarcinoma that has spread to other places in the body or that cannot be removed by surgery.
- Conditions
- Metastatic Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Carcinoma, Unresectable Small Intestinal Carcinoma
- Trial name
- NCT02949219
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Academic and Community Cancer Research United
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Cutaneous Melanoma
A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery
The purpose of this study is to find out what patients consider when deciding whether or not to receive adjuvant treatment, and how patients feel about their decision after one year.
- Trial name
- NCT03843593
- Testing
- Demographics Questionnaire, Adjuvant Treatment Beliefs Scale10, Functional Assessment of Cancer Therapy - Melanoma (FACT-M)11
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urothelial Cancer
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations
The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who…
- Trial name
- THOR (NCT03390504)
- Testing
- Erdafitinib, Vinflunine, Docetaxel
- Where
- 345 sites in United States, Argentina and 25 more
- Volunteers
- 629 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancers, Triple Negative Breast Cancer (TNBC)
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
OPT-PEMBRO trial is a pragmatic, multicentre, international, prospective, non-inferiority, two-arms, randomised (1:1), open-label, Phase III clinical study.
- Trial name
- OPT-PEMBRO (NCT06606730)
- Testing
- Pembrolizumab, Deescalation
- Where
- 2 sites in Belgium, France
- Volunteers
- 2,454 people
- Sponsor
- UNICANCER
Colorectal Cancer, Endometrium Cancer
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
Single Center, open label, Phase I-II trial designed to test the safety and efficacy of the combination of Ataluren and Pembrolizumab for the treatment of metastatic mismatch repair deficient and proficient colorectal…
- Trial name
- ATAPEMBRO (NCT04014530)
- Testing
- Ataluren + Pembrolizumab
- Where
- Netherlands
- Volunteers
- 47 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Advanced Or Metastatic Merkel Cell Carcinoma
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with…
- Trial name
- NCT06947928
- Testing
- IFx-Hu2.0, Pembrolizumab
- Where
- 18 sites in United States
- Volunteers
- 118 people
- Sponsor
- TuHURA Biosciences, Inc.
Lymphoma, Relapsed
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma.
- Conditions
- Lymphoma, Relapsed, Refractory
- Trial name
- NCT03179930
- Testing
- Entinostat, Pembrolizumab
- Where
- 9 sites in United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Classical Hodgkin Lymphoma
Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above
This is a multi-center, open-label phase II study to assess the efficacy of a novel fitness-adapted regimen in previously untreated older patients with classical Hodgkin lymphoma.
- Trial name
- NCT05404945
- Testing
- Pembrolizumab, Doxorubicin, Vinblastine
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Virginia
Biliary Tract Cancer
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
The term of biliary tract cancer (BTC) or cholangiocarcinoma refers to all tumors that arise from the biliary tract or the biliary drainage system, including the gallbladder.
- Trial name
- NCT03937895
- Testing
- 'SMT-NK' Inj (allogeneic Natural Killer cell), Pembrolizumab Injection [Keytruda]
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- SMT bio Co., Ltd.
Esophageal Cancer, Squamous Cell Esophagus Cancer
Pembrolizumab in Refractory Advanced Esophageal Cancer
This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab
- Conditions
- Esophageal Cancer, Squamous Cell Esophagus Cancer, Adenocarcinoma Esophagus
- Trial name
- NCT02971956
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma, Melanoma Stage III
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
This is a phase 2, single-arm, open label clinical trial determining efficacy of Cyclophosphamide and Pembrolizumab in subjects with melanoma.
- Conditions
- Melanoma, Melanoma Stage III, Melanoma (Skin), Melanoma Stage IV
- Trial name
- NCT06771544
- Testing
- Pembrolizumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of California, Irvine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.